Business Context and Reporting Period
This Form 8-K Current Report was filed by Abbott Laboratories on February 17, 2023. The report addresses a corporate governance amendment regarding the company's Board of Directors.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is not a financial statement filing and contains no quantitative financial data.
Material Changes
The primary material change disclosed is an amendment to the company's by-laws:
- Board Size Reduction: The Board of Directors amended Article III, Section 2 of the by-laws to reduce the number of directors from thirteen to twelve.
- Effective Date: This change is effective as of April 28, 2023.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the procedural announcement of the by-law amendment.
Key Facts for Investor Verification
- Verify the effective date of the Board size reduction (April 28, 2023).
- Confirm the new total number of directors (twelve) versus the previous count (thirteen).
- Review the attached Exhibit 3.1 for the full text of the amended and restated By-Laws.